Biomaterials and design in occlusion devices for cardiac defects: A review

HuangY.; KongJ.F.; VenkatramanS.S.

首页> 外文期刊>Acta biomaterialia >Biomaterials and design in occlusion devices for cardiac defects: A review

【24h】

Biomaterials and design in occlusion devices for cardiac defects: A review

机译：心脏缺陷阻塞装置的生物材料和设计：综述

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This review examines the biomaterials used in occlusion devices for cardiac defects, and how the choice of these materials is dictated by design. Specifically, the devices used in three major applications, the atrial septal defect, the ventricular septal defect and the patent ductus arteriosus, are examined critically. A number of different devices are available, with varied performance in deployment and sealing. There is no device in any of the three categories that satisfies fully the range of requirements, and all have associated complications. The type and rate of complications are different among different devices. The short-term (immediate) complications are addressed by immediate retrieval. For longer-term complications, most of which can be fatal, currently only surgical retrieval and replacement are possible. Most of these longer-term complications can be alleviated by the use of fully degradable devices, which will eliminate concerns regarding the use of metals inside the heart, and if fully endothelialized, also minimize migration concerns. On the other hand, the lower moduli of currently available biodegradable materials need to be augmented. Improvements in the stiffness required for deployment can be accomplished with the use of fillers, nano- or micro-sized, and an example of this are radiopaque fillers.

机译：这篇综述研究了用于心脏缺陷的闭塞装置中使用的生物材料，以及如何通过设计决定这些材料的选择。具体来说，对三大应用中的设备（房间隔缺损，室间隔缺损和动脉导管未闭）进行了严格检查。提供了许多不同的设备，它们在部署和密封方面具有不同的性能。在这三个类别中，没有一个能够完全满足要求的设备，并且都具有相关的并发症。不同设备之间并发症的类型和发生率也不同。短期（立即）并发症可通过立即检索来解决。对于长期并发症，其中大多数可能是致命的，目前只能进行外科手术取回和置换。通过使用完全可降解的设备，可以缓解大多数这些较长期的并发症，这将消除对心脏内部使用金属的担忧，并且如果完全内皮化，也可以最大程度地减少迁移问题。另一方面，当前可用的可生物降解材料的较低模量需要增加。可以通过使用纳米或微米尺寸的填充剂来实现部署所需的刚度的改善，不透射线的填充剂就是一个例子。

著录项

来源
《Acta biomaterialia》 |2014年第3期|共14页
作者
HuangY.; KongJ.F.; VenkatramanS.S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类普通生物学;
关键词
Atrial septal defect; Biomaterials; Occlusion device; Patent ductus arteriosus; Ventricular septal defect;

机译：房间隔缺损;生物材料;阻塞装置;动脉导管未闭;室间隔缺损;

相似文献

外文文献
中文文献
专利

1. Biomaterials and design in occlusion devices for cardiac defects: A review [J] . HuangY., KongJ.F., VenkatramanS.S. Acta biomaterialia . 2014,第3期

机译：心脏缺陷阻塞装置的生物材料和设计：综述
2. Flow Simulation of Cardiac Defects to Evaluate Effectiveness of Occlusion Devices [J] . Vaibhavi A. Sonetha, Jayesh R. Bellare Journal of Medical Devices . 2014,第2期

机译：心脏缺损的血流模拟，以评估阻塞装置的有效性
3. Rebuttal with regards to “Device‐associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet” [J] . Lempereur M., Aminian A., Saw J. Catheterization and cardiovascular interventions: Official journal of the Society for Cardiac Angiography & Interventions . 2018,第3期

机译：关于“左心房附属闭塞后的设备相关血栓形成的反驳：对守望者，Amplatzer心脏插头和护身符报告的事件系统审查”
4. ( 372-0041) Evaluation of Mechanical Behavior of Occlusion Devices for Atrial Septal Defects [C] . Jiaming YANG, Takayuki SHIRAIWA, Manabu ENOKI 日本金属学会秋期大会 . 2017

机译：（372-0041）对房地间隔缺损的闭塞装置力学行为的评价
5. Combinatorial design and development of biomaterials for use as drug delivery devices and immune adjuvants [D] . Petersen, Latrisha Kay 2011

机译：用作药物输送装置和免疫佐剂的生物材料的组合设计和开发
6. Design for Additive Bio-Manufacturing: From Patient-Specific Medical Devices to Rationally Designed Meta-Biomaterials [O] . Amir A. Zadpoor 2017

机译：增材制造的设计：从患者特定的医疗设备到合理设计的超生物材料
7. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) 11This document was approved by the American College of Cardiology Foundation Board of Trustees in September 2002, the American Heart Association Science Advisory and Coordinating Committee in August 2002, and the North American Society for Pacing and Electrophysiology in August 2002.22The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. The conflict of interest information for the writing committee members is posted on the ACC, AHA, and NASPE Web sites with the full-length version of the update.33When citing this document, the ACC, the AHA, and NASPE would appreciate the following citation format: Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol2002;40:1703–19.44Copies: This document is available on the World Wide Web sites of the ACC (www.acc.org) and the AHA (www.americanheart.org). A single copy of the complete guidelines is available by calling 800-253-4636 (US only) or writing the American College of Cardiology, Resource Center, 9111 Old Georgetown Road, Bethesda, MD 20814-1699 (ask for No. 71-0237). To obtain a copy of the Summary Article, ask for reprint No. 71-0236. To purchase additional reprints (specify version and reprint number): up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail kbradle@lww.com.55(J Am Coll Cardiol 2002;40:1703–19.)66©2002 by the American College of Cardiology Foundation and the American Heart Association, Inc. [O] . Gregoratos Gabriel, Abrams Jonathan, Epstein Andrew E, 2002

机译：ACC / AHA / NASPE 2002心脏起搏器和抗心律失常装置植入指南更新-总结文章美国心脏病学会/美国心脏协会实践指南工作组的报告（ACC / AHA / NASPE委员会将更新1998年起搏器指南） 11该文件于2002年9月获得美国心脏病学会基金会董事会的批准，于2002年8月获得美国心脏协会科学咨询和协调委员会的批准，并于2002年8月获得北美起搏和电生理学会的批准。22ACC / AHA工作组《实践指南》将尽一切努力避免由于写作小组成员的外部关系或个人利益而引起的任何实际或潜在的利益冲突。具体来说，要求写作小组的所有成员提供所有可能被视为实际或潜在利益冲突的关系的披露声明。这些声明由上级工作组审核，在第一次会议上口头报告给写作小组的所有成员，并在发生变化时进行更新。撰写委员会成员的利益冲突信息已发布在更新的完整版本的ACC，AHA和NASPE网站上。33当引用本文档时，ACC，AHA和NASPE将不胜感激。格式：Gregoratos G，Abrams J，Epstein AE，Freedman RA，Hayes DL，Hlatky MA，Kerber RE，Naccarelli GV，Schoenfeld MH，Silka MJ，Winters SL。 ACC / AHA / NASPE 2002心脏起搏器和抗心律失常装置植入指南更新-总结文章：美国心脏病学会/美国心脏协会实践指南工作组的报告（ACC / AHA / NASPE委员会更新了1998年起搏器指南）。 J Am Coll Cardiol2002； 40：1703–19.44复制：此文档可在ACC（www.acc.org）和AHA（www.americanheart.org）的万维网站点上找到。您可以致电800-253-4636（仅限美国）或写信给美国心脏病学会资源中心，地址为9111 Old Georgetown Road，Bethesda，MD 20814-1699，获得一份完整的指南（请致电71-0237））。要获得摘要文章的副本，请索要第71-0236号转载。要购买其他重印本（指定版本和重印本号码）：最多999份，请致电800-611-6083（仅限美国）或传真413-665-2671；否则，请重新发送。 1000份或更多，请致电410-528-4426，传真410-528-4264或发送电子邮件至kbradle@lww.com.55（J Am Coll Cardiol 2002； 40：1703–19。）66©2002美国心脏病学基金会基金会和美国心脏协会有限公司

Biomaterials and design in occlusion devices for cardiac defects: A review

摘要

著录项

相似文献

相关主题

期刊订阅